Effect of Azilsartan on Aldosterone in Postmenopausal Females

• Status: Completed
• Trial end date: 2016-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of the research is to evaluate the effect of azilsartan medoximil on blood pressure and urinary aldosterone levels in postmenopausal females.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Chicago
• Collaborator: Takeda
• Treatments: Azilsartan medoxomil

Criteria

Inclusion Criteria:

• Female

• Ages 45-70

• Post-menopause: have not had a menstrual period for one year or more

• Diagnosed with Stage 1 hypertension

• Body Mass Index (BMI) greater than or equal to 28

Exclusion Criteria:

• Male

• Diagnosed with Stage 2 hypertension

• Stage 1 hypertension requiring more than one agent

• Pregnancy or attempting pregnancy

• Use of oral contraceptive pills

• Use of hormone replacement therapy

• Use of steroids

• Stage 3 or greater kidney disease

• Diabetes mellitus

• untreated hypothyroidism or hyperthyroidism

• primary hyperaldosteronism

• Cushing's disease

• obstructive sleep apnea

• chronic illness, e.g. chronic liver disease

• NYHA class III or greater heart failure

• moderate to severe lung disease